Novel Combination of <scp>UVA</scp> ‐1 Phototherapy With Topical Tofacitinib for Treating Eosinophilic Fasciitis With Morphea: Case Report
Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic corticosteroids, intravenous immunoglobulin, and methotrexate for EF. A novel combination of topical tofacitinib, a Janus kinase (JAK) inhibitor, and UVA-1 phototherapy induced clinical remission and was well tolerated, warranting further investigation into such combination therapy.
Authors
- Frankie O. G. Fraulin (ORCID: https://orcid.org/0000-0001-8295-7794)
- Michele Ramien (ORCID: https://orcid.org/0000-0001-9191-3611)
- Nadia Luca (ORCID: https://orcid.org/0000-0001-7754-7213)
- Ye‐Jean Park
- Daphne Cheung (ORCID: https://orcid.org/0009-0003-7881-192X)
- Marie‐Anne Bründler (ORCID: https://orcid.org/0000-0002-5323-5765)
Institutions
- University of Toronto (CA)
- Alberta Children's Hospital (CA)
Publication Details
- Journal
- Pediatric Dermatology
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1111/pde.70220
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00